Ousted FDA vaccine director calls Kennedy’s start ‘very scary’
Peter Marks, the Food and Drug Administration (FDA) official pressured to resign over his disagreements with Health and Human ...
STAT4h
Science panel’s advice for next dietary guidelines could be on collision course with MAHA
The Dietary Guidelines for America are due by the end of the year, but Trump administration statements raise doubts as to ...
Ousted vaccine official says Kennedy sought data to justify anti-science stance, WSJ reports
Peter Marks, the FDA's top vaccine official ousted by Robert F. Kennedy Jr. said the U.S. health secretary's team sought ...
Ousted Vaccine Chief Says RFK Jr.’s Team Sought Data to Justify Anti-Science Stance
Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...
RFK Jr. to reinstate 20% of HHS staff laid off after DOGE errors
HHS Secretary Robert F. Kennedy, Jr. plans to reinstate 20% of recently laid-off staff due to errors in restructuring. Read ...
Fierce Pharma9h
GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Chapelboro10h
Here’s Where Jobs and Programs Are Being Cut at the Nation’s Top Health Agencies
Thousands of people were laid off Tuesday at the United States' top health agencies. Here are what positions and efforts were ...
Vermont Community Newspaper Group10h
FDA Delays Final Approval of Novavax COVID Vaccine
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, ...
11 Stocks to Buy After the Biotech Bloodbath
The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.
The Value of Moderna's mRNA Technology Is Obscured by Fears of a Hostile US Regulatory Environment
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...